摘要
为了评价放疗联合同期化疗对不能手术的Ⅲ期非小细胞肺癌(non—small cell lung cancer,NSCLC)的疗效。将81例患者随机分为2组:同期放化疗组41例患者。在放疗的同时每周接受顺铂(DDP)30mg/m^2的化疗。共用6用,于第1、8天接受长春瑞滨(NVB)25mg/m^2的化疗。每3周1次;序贯放化疗组40例患者均接受NVB与DDP的诱导化疗2个疗程,然后放疗。两组放疗方法相同,每周10Gy,共60~70Gy。结果同期放化疗组和序贯放化疗组的总有效率分别为80.5%(33/41)和60.0%(24/40).差异有统计学意义,P=0.043,完全缓解率分别是19.5%(8/41)和12.5%(6/40),差异无统计学意义,P=0.591。中位生存时间分别为15.8和13.1个月,差异有统计学意义,P=0.032。主要的不良反应是放射性食管炎、放射性肺炎与骨髓抑制,差异有统计学意义,P=0.032。初步研究结果提示,放疗联合NVB与DDP的同期化疗延长了不能手术的Ⅲ期NSCLC的生存期。
To evaluate the effect of radiotherapy combined with the concurrent chemotherapy for unreseetable stage Ⅲ non-small cell lung cancer (NSCLC). 8 patients with unresectable stage Ⅲ NSCLC were randomized to two groups. 41 patients in the concurrent arm received weekly cisplatin (30 mg/m^2) for 6 weeks with vinorelbine (25 mg/m^2 ) on d1 and d8, every 3 weeks during concurrent radiation. 40 patients in the sequential arm received two cycles eisplatin (90 mg/m^2) on d1 and vinorelbine (25 mg/m^2) on d1 and d8 every 3 weeks followed by radiation. The method of radiation was the same in the two groups, with a dose of 60-70 Gy of radiation over 6-7 weeks. Response rate was 80. 5 % (33/41) in the concurrent arm and 60.0% (24/40) in the sequential arm. The difference in response rate between the concurrent arm and the sequential arm was significant, P=0. 043. Complete response rate was 19.5% (8/41) in the concurrent arm and 12.5 % (5/40) in the sequential arm. The difference was not significant, P= 0. 591. Median survival time was 15.8 months in the concurrent arm and 13.1 months in the sequential arm. The difference was significant, P=0. 032. The radiotherapy combined with concurrent chemotherapy is a kind of efficient treatment for patients with unresectable stage Ⅲ NSCLC.
出处
《中华肿瘤防治杂志》
CAS
2006年第23期1822-1823,共2页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺
肺肿瘤/放射疗法
肺肿瘤/药物疗法
carcinoma, non-small cell lung
lung neoplasms/radiatherapy
lung neoplasms/drug therapy